The evolution of commercial drug delivery technologies
Drug delivery technologies have enabled the development of many pharmaceutical
products that improve patient health by enhancing the delivery of a therapeutic to its target …
products that improve patient health by enhancing the delivery of a therapeutic to its target …
Clinical cancer immunotherapy: Current progress and prospects
C Liu, M Yang, D Zhang, M Chen, D Zhu - Frontiers in immunology, 2022 - frontiersin.org
Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …
robust therapeutic potential in clinical practice. It can significantly improve progression-free …
Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses
Increasing evidence implicates the tumor microbiota as a factor that can influence cancer
progression. In patients with colorectal cancer (CRC), we found that pre-resection antibiotics …
progression. In patients with colorectal cancer (CRC), we found that pre-resection antibiotics …
Biomineralized two‐enzyme nanoparticles regulate tumor glycometabolism inducing tumor cell pyroptosis and robust antitumor immunotherapy
S Zhang, Y Zhang, Y Feng, J Wu, Y Hu, L Lin… - Advanced …, 2022 - Wiley Online Library
Currently, immune checkpoint therapy combined with chemotherapy and radiotherapy is a
useful strategy for improving immunotherapy's therapeutic efficacy. However, chemotherapy …
useful strategy for improving immunotherapy's therapeutic efficacy. However, chemotherapy …
Enhancing cancer immunotherapy with nanomedicine
Therapeutic targeting of the immune system in cancer is now a clinical reality and marked
successes have been achieved, most notably through the use of checkpoint blockade …
successes have been achieved, most notably through the use of checkpoint blockade …
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Multiple nanotherapeutics have been approved for patients with cancer, but their effects on
survival have been modest and, in some examples, less than those of other approved …
survival have been modest and, in some examples, less than those of other approved …
Delivery technologies for cancer immunotherapy
Immunotherapy has become a powerful clinical strategy for treating cancer. The number of
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …
Boosting checkpoint immunotherapy with biomaterials
The immune checkpoint blockade (ICB) therapy has revolutionized the field of cancer
treatment, while low response rates and systemic toxicity limit its clinical outcomes. With the …
treatment, while low response rates and systemic toxicity limit its clinical outcomes. With the …
Massively evoking immunogenic cell death by focused mitochondrial oxidative stress using an AIE luminogen with a twisted molecular structure
Immunogenic cell death (ICD) provides momentous theoretical principle for modern cancer
immunotherapy. However, the currently available ICD inducers are still very limited and …
immunotherapy. However, the currently available ICD inducers are still very limited and …
Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy
Activation of scramblases is one of the mechanisms that regulates the exposure of
phosphatidylserine to the cell surface, a process that plays an important role in tumour …
phosphatidylserine to the cell surface, a process that plays an important role in tumour …